Truist Securities Reiterates Buy on Roivant Sciences, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and maintained a price target of $23.
July 14, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $23.
The reiterated 'Buy' rating and maintained price target by Truist Securities indicates a positive outlook for Roivant Sciences. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100